X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 292.3 67.4 433.8% View Chart
P/BV x 32.4 13.6 238.9% View Chart
Dividend Yield % 1.4 1.1 132.8%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GSK PHARMA
Mar-18
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7582,760 27.5%   
Low Rs5792,040 28.4%   
Sales per share (Unadj.) Rs228.4339.0 67.4%  
Earnings per share (Unadj.) Rs31.741.4 76.6%  
Cash flow per share (Unadj.) Rs32.845.9 71.4%  
Dividends per share (Unadj.) Rs10.0035.00 28.6%  
Dividend yield (eoy) %1.51.5 102.6%  
Book value per share (Unadj.) Rs297.1242.9 122.3%  
Shares outstanding (eoy) m24.6984.70 29.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.97.1 41.3%   
Avg P/E ratio x21.157.9 36.3%  
P/CF ratio (eoy) x20.452.3 39.0%  
Price / Book Value ratio x2.29.9 22.8%  
Dividend payout %31.584.5 37.3%   
Avg Mkt Cap Rs m16,505203,280 8.1%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,4455,234 27.6%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,63928,715 19.6%  
Other income Rs m1,718545 315.0%   
Total revenues Rs m7,35729,260 25.1%   
Gross profit Rs m-635,059 -1.2%  
Depreciation Rs m25380 6.7%   
Interest Rs m552 2,765.0%   
Profit before tax Rs m1,5755,222 30.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m7921,892 41.8%   
Profit after tax Rs m7843,508 22.3%  
Gross profit margin %-1.117.6 -6.3%  
Effective tax rate %50.336.2 138.7%   
Net profit margin %13.912.2 113.7%  
BALANCE SHEET DATA
Current assets Rs m9,52221,815 43.6%   
Current liabilities Rs m3,29615,999 20.6%   
Net working cap to sales %110.420.3 545.1%  
Current ratio x2.91.4 211.9%  
Inventory Days Days3764 57.6%  
Debtors Days Days2819 152.1%  
Net fixed assets Rs m4612,475 0.4%   
Share capital Rs m123847 14.6%   
"Free" reserves Rs m7,21319,726 36.6%   
Net worth Rs m7,33620,573 35.7%   
Long term debt Rs m06 0.0%   
Total assets Rs m11,10539,475 28.1%  
Interest coverage x29.52,612.0 1.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 69.8%   
Return on assets %7.68.9 85.0%  
Return on equity %10.717.1 62.6%  
Return on capital %22.226.2 84.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m61564 10.7%   
Fx outflow Rs m3,6307,429 48.9%   
Net fx Rs m-3,570-6,865 52.0%   
CASH FLOW
From Operations Rs m1,6104,728 34.1%  
From Investments Rs m687-1,042 -65.9%  
From Financial Activity Rs m-2,677-3,066 87.3%  
Net Cashflow Rs m-380620 -61.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 14, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS